Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · IEX Real-Time Price · USD
13.02
+0.03 (0.23%)
May 3, 2024, 4:30 PM EDT - Market closed

Skye Bioscience Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017201620152014 2013 - 2012
Cash & Equivalents
10.341.258.992.471.831.860.260.13.260.21
Upgrade
Cash & Cash Equivalents
10.341.258.992.471.831.860.260.13.260.21
Upgrade
Cash Growth
727.52%-86.10%263.28%34.86%-1.26%602.72%158.39%-96.86%1471.75%-
Upgrade
Other Current Assets
1.317.690.620.190.160.10.290.180.20.1
Upgrade
Total Current Assets
11.658.949.612.661.991.950.560.283.450.31
Upgrade
Property, Plant & Equipment
0.280.160.230.010000.010.010.02
Upgrade
Other Long-Term Assets
0.010.010.0100000.030.040.02
Upgrade
Total Long-Term Assets
0.290.170.240.010000.040.060.04
Upgrade
Total Assets
11.949.119.862.6721.960.560.323.510.35
Upgrade
Accounts Payable
1.161.790.90.380.140.020.10.270.130.41
Upgrade
Current Debt
4.441.932.060.06000.24000
Upgrade
Other Current Liabilities
8.38.40.950.340.8315.920.470.390.460.39
Upgrade
Total Current Liabilities
13.912.123.910.790.9715.940.810.660.580.8
Upgrade
Long-Term Debt
0.1700.081.430.391.360000
Upgrade
Other Long-Term Liabilities
00000.090.220.551.112.460
Upgrade
Total Long-Term Liabilities
0.1700.081.430.481.580.551.112.460
Upgrade
Total Liabilities
14.0712.123.992.221.4517.521.361.773.040.8
Upgrade
Total Debt
4.621.932.141.50.391.360.24000
Upgrade
Debt Growth
139.50%-9.78%42.61%286.96%-71.56%479.13%----
Upgrade
Retained Earnings
-104.38-66.74-47.26-38.73-32.17-33.23-14.03-10.94-7.76-2.92
Upgrade
Shareholders' Equity
-2.13-3.015.860.450.55-15.56-3.57-2.91-0.89-0.45
Upgrade
Net Cash / Debt
5.72-0.686.850.981.450.50.030.13.260.21
Upgrade
Net Cash / Debt Growth
--601.88%-32.56%191.28%1591.20%-71.28%-96.86%1471.75%-
Upgrade
Net Cash Per Share
0.82-0.314.211.052.131.030.261.3548.105.04
Upgrade
Working Capital
-2.25-3.185.71.881.02-13.99-0.25-0.382.87-0.49
Upgrade
Book Value Per Share
-0.30-1.353.610.491.01-32.11-31.98-38.45-13.17-11.02
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).